[1] Topalian SL, Sznol M,McDermott DF,et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab[J]. J Clin Oncol,2014,32:1020. [2] Galluzzi L, Zitvogel L, Kroemer G. Immunological mechanisms underneath the effcacy of cancer therapy[J]. Cancer Immunol Res,2016, 4(11): 895. [3] Huang Y, Stylianopoulos T, Duda DG, et al. Benefts of vascular normalization are dose and time dependent-letter[J]. Cancer Res,2013, 73(23): 7144. [4] Locy H, de Mey S,de Mey W,et al. Immunomodulation of the tumor microenvironment: turn foe into friend[J]. Front Immunol,2018, 9: 29092. [5] Hammerich L, Bhardwaj N, Kohrt HE,et al. In situ vaccination for the treatment of cancer[J]. Immunotherapy,2016, 8: 315. [6] Ma Y, Pitt JM, Li Q, et al. The renaissance of anti-neoplastic immunity from tumor cell demise[J].Immunol Rev,2017, 280:194. [7] Sharabi AB, Lim M, de Weese TL, et al. Radiation and checkpoint blockadeimmunotherapy:radiosensitivition and potential mechanisms of synergy[J]. Lancet Oncol,2015,16(13):e498. [8] Gandhi S, Chandna S. Radiation-induced inflammatory cascade and its reverberating crosstalks as potential cause of post-radiotherapy second malignancies[J]. Cancer Metastasis Rev,2017, 36: 375. [9] Tsoutsou PG, Zaman K, Martin LS, et al. Emerging opportunities of radiotherapy combined with immunotherapy in the era of breast cancer heterogeneity[J]. Front Oncol,2018, 8: 609. [10] Mukherjee S, Chakraborty A. Radiation-induced bystander phenomenon: Insight and implications in radiotherapy[J]. Int J Radiat Biol,2019, 95: 243. [11] Frey B, Rubner Y, Wunderlich R, et al. Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation-implications for cancer therapies[J]. Curr Med Chem,2012, 19: 1751. [12] McKelvey J, Hudson L, Back M, et al. Radiation, inflammation and the immune response in cancer[J]. Mamm Genome,2018, 29: 843. [13] Wennerberg E, Lhuillier C,Vanpouille-Box C, et al. Barriers to radiation-induced in situ tumor vaccination[J]. Front Immunol,2017,8: 229. [14] Ebner K, Tinganelli W, Helm A, et al. The immunoregulatory potential of particle radiation in cancer therapy[J]. Front Immunol,2017, 8: 99. [15] Manda K, Glasow A, Paape D, et al.Effects of ionizing radiation on the immune system with special emphasis on the interaction of dendritic and T cells[J]. Front Oncol,2012, 2:102. [16] Deloch L, Derer A, Hartmann J, et al. Modern radiotherapy concepts and the impact of radiation on immune activation[J]. Front Oncol,2016, 6:141. [17] Mole RH. Whole body irradiation-radiobiology or medicine?[J].Br J Radiol,1953,26(305):234. [18] 刘超.NSCLC立体定向放疗和常规分割放疗的免疫效应及相关临床分析[D].合肥:安徽医科大学,2017. [19] Gupta A, Probst UC, Vuong V,et al, Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation[J].J Immunol,2012,189(2):558. [20] Rückert M, Deloch L, Fietkau R, et al. Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies[J]. Strahlenther Onkol,2018, 194: 509. [21] Hellevik T, Martinez-Zubiaurre I. Radiotherapy and the tumor stroma: The importance of dose and fractionation[J]. Front Oncol,2014, 4:1. [22] Arnold M, Flynn J, Raben A, et al. The impact of radiation on the tumor microenvironment: effect of dose and fractionation schedules[J]. Cancer Growth Metastasis,2018,11:1179064418761639. [23] Jeong H, Bok S, Hong J, et al. Radiation-induced immune responses: mechanisms and therapeutic perspectives[J]. Blood Res,2016, 51: 157. [24] Tsoutsou G, Zaman K, Martin S,et al. Emerging opportunities of radiotherapy combined with immunotherapy in the era of breast cancer heterogeneity[J]. Front Oncol,2018, 8: 609. [25] Shevtsov M, Sato H, Multhoff G, et al. Novel approaches to improve the efficacy of immuno-radiotherapy[J]. Front Oncol,2019, 9:156. [26] Kleibeuker A, Griffioen W, Verheul M, et al. Combining angiogenesis inhibition and radiotherapy: A double-edged sword[J]. Drug Resist Updates,2012, 15:173. [27] Beyranvand Nejad E, Welters MJ, Arens R,et al. The importance of correctly timing cancer immunotherapy[J]. Expert Opin Biol Ther,2017, 17:87. [28] Klug F, Prakash H, Huber PE, et al. Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy[J]. Cancer Cell,2013, 24:589. [29] Schaue D, McBride H. Opportunities and challenges of radiotherapy for treating cancer[J]. Nat Rev Clin Oncol,2015, 12: 527. [30] Ostrand-Rosenberg S, Horn A, Ciavattone G. Radiotherapy both promotes and inhibits myeloid-derived suppressor cell function: Novel strategies for preventing the tumor-protective effects of radiotherapy[J]. Front Oncol,2019, 9:215. [31] Yin LM, Xue JX, Li R, et al. Effect of low-dose radiotherapy on abscopal responses to hypofractionated radiotherapy and anti-PD1 in mice and NSCLC patients nternational[J]. Journal of Radiation Oncology, Biology, Physics,2020,108(3):e563. [32] Garrett M, Wang TJC, Cheng SK, et al. Combined versus sequential radiation and immunotherapy in advanced lung cancer[J]. Int J Radiat Oncol Biol Phys, 2017,99(2):E455. [33] Young KH, Baird JR, Savage T, et al. Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy[J]. PLoS One,2016,11(6):e0157164. [34] Zheng X, Fang Z, Liu X, et al. Increased vessel perfusion predicts the efficacy of immune checkpoint blockade[J]. The Journal of Clinical Investigation,2018,128:2104. [35] Grassberger C, Ellsworth SG, Wilks MQ, et al. Assessing the interactions between radiotherapy and antitumour immunity[J]. Nat Rev Clin Oncol,2019,16:729. |